John McKolanis

John McKolanis

Auto-generated profile, based on publicly available information

John McKolanis

Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
DCDaniel W. Cramer
Daniel W. Cramer
LTLinda Titus-Ernstoff
Linda Titus-Ernstoff
JMJohn R. McKolanis
John R. McKolanis
WWWilliam R. Welch
William R. Welch
AVAllison F. Vitonis
Allison F. Vitonis
OFOlivera Finn
Olivera Finn
Many cancers, including ovarian, overexpress epithelial mucin (MUC1) and promote anti-MUC1 antibodies that may correlate with more favorable prognosis. By extension, risk for ovarian cancer might be reduced by preexisting MUC1-specific immunity. We measured anti-MUC1 antibodies in 705 control women, identified events predicting antibodies, and estimated ovarian cancer risk by comparing profiles of events generating antibodies in controls with those in 668 ovarian cancer cases. Factors predicting antibodies included oral contraceptive use, breast mastitis, bone fracture or osteoporosis, pelvic surgeries, nonuse of talc in genital hygiene, and to a lesser extent intrauterine device use and current smoking. There was a significant increase in the likelihood of having anti-MUC1 antibodies from 24.2% in women with 0 or 1 condition, to 51.4% in those with five or more conditions. By the same index of events, the risk for ovarian cancer was inversely associated with number of conditions predisposing to anti-MUC1 antibodies. Compared with having experienced 0 or 1 event, the adjusted risk for ovarian cancer decreased progressively with relative risks (and 95% confidence limits) of 0.69 (0.52-0.92), 0.64 (0.47-0.88), 0.49 (0.34-0.72), and 0.31 (0.16-0.61), respectively for women with two, three, four, and five or more events related to the presence of antibodies (Ptrend < 0.0001.) We conclude that several traditional and new risk factors for ovarian cancer may be explained by their ability to induce MUC1 immunity through exposure of MUC1 to immune recognition in the context of inflammatory or hormonal processes in various MUC1-positive tissues.

9 March 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RSRobert E. Schoen
Robert E. Schoen
LBLisa Boardman
Lisa Boardman
MCMarcia Cruz-Correa
Marcia Cruz-Correa
ABAjay Bansal
Ajay Bansal
DKDavid Kastenberg
David Kastenberg
OFOlivera Finn
Olivera Finn
Purpose: To assess whether MUC1 peptide vaccine produces an immune response and prevents subsequent colon adenoma formation. Patients and Methods: Multicenter, double-blind, placebo-controlled randomized trial in individuals age 40 to 70 with diagnosis of an advanced adenoma ≤1 year from randomization. Vaccine was administered at 0, 2, and 10 weeks with a booster injection at week 53. Adenoma recurrence was assessed ≥1 year from randomization. The primary endpoint was vaccine immunogenicity at 12 weeks defined by anti-MUC1 ratio ≥2.0. Results: Fifty-three participants received the MUC1 vaccine and 50 placebo. Thirteen of 52 (25%) MUC1 vaccine recipients had a ≥2-fold increase in MUC1 IgG (range, 2.9–17.3) at week 12 versus 0/50 placebo recipients (one-sided Fisher exact P < 0.0001). Of 13 responders at week 12, 11 (84.6%) responded to a booster injection at week 52 with a ≥2-fold increase in MUC1 IgG measured at week 55. Recurrent adenoma was observed in 31 of 47 (66.0%) in the placebo group versus 27 of 48 (56.3%) in the MUC1 group [adjusted relative risk (aRR), 0.83; 95% confidence interval (CI), 0.60–1.14; P = 0.25]. Adenoma recurrence occurred in 3/11 (27.3%) immune responders at week 12 and week 55 (aRR, 0.41; 95% CI, 0.15–1.11; P = 0.08 compared with placebo). There was no difference in serious adverse events. Conclusions: An immune response was observed only in vaccine recipients. Adenoma recurrence was not different than placebo, but a 38% absolute reduction in adenoma recurrence compared with placebo was observed in participants who had an immune response at week 12 and with the booster injection.

29 November 2015 in Disease Markers
Verified
Journal Article
Open access
PDF file
EMEbru Menekse
Ebru Menekse
JMJohn McKolanis
John McKolanis
OFOlivera Finn
Olivera Finn
PMPriscilla F. McAuliffe
Priscilla F. McAuliffe
RJRonald Johnson
Ronald Johnson
ASAtilla Soran
Atilla Soran
Antibodies against MUC1 are found in circulation of breast cancer (BC) patients. We hypothesized that anti-MUC1 antibodies might be present in even a higher concentration in nipple aspirate fluid (NAF) and could be used to predict aggressiveness of BC. Serum and NAF samples were collected from high risk lesions, BC, and healthy contralateral breasts. ELISA was used to measure the amount of IgG, IgM, and IgA against a tumor-specific MUC1 peptide derived from the extracellular tandem repeat domain of MUC1. Tumor characteristics were recorded prospectively; 120 NAF samples were obtained from a total of 77 women in the study. There was no significant difference of anti-MUC1 antibody levels compared to BC with other lesions. Anti-MUC1 IgG level in NAF was higher in triple negative tumors (P=0.02); serum anti-MUC1 IgG levels were significantly higher in patients with ER (−) tumor and recurrent disease (P=0.01); NAF anti-MUC1 IgA levels were significantly higher in patients with LVI and Her2-neu (+) tumors (P<0.05). These results show that NAF could be a reliable biomarker to predict tumor aggressiveness in BC. A larger study will be needed to confirm these data and to investigate the potential of anti-MUC1 antibodies in NAF and serum to predict disease outcome.

25 November 2025
Verified
Other
Open access
RSRobert E. Schoen
Robert E. Schoen
LBLisa Boardman
Lisa Boardman
MCMarcia Cruz-Correa
Marcia Cruz-Correa
ABAjay Bansal
Ajay Bansal
DKDavid Kastenberg
David Kastenberg
OFOlivera Finn
Olivera Finn
Supplementary methods: Detailed laboratory methods

25 November 2025
Verified
Other
Open access
RSRobert E. Schoen
Robert E. Schoen
LBLisa Boardman
Lisa Boardman
MCMarcia Cruz-Correa
Marcia Cruz-Correa
ABAjay Bansal
Ajay Bansal
DKDavid Kastenberg
David Kastenberg
OFOlivera Finn
Olivera Finn
Supplementary methods: trial administration

25 November 2025
Verified
Other
Open access
RSRobert E. Schoen
Robert E. Schoen
LBLisa Boardman
Lisa Boardman
MCMarcia Cruz-Correa
Marcia Cruz-Correa
ABAjay Bansal
Ajay Bansal
DKDavid Kastenberg
David Kastenberg
OFOlivera Finn
Olivera Finn
Baseline advanced adenoma characteristics